The General Hospital Corporation

United States of America

Back to Profile

1-100 of 4,541 for The General Hospital Corporation Sort by
Query
Excluding Subsidiaries
Aggregations Reset Report
IP Type
        Patent 4,486
        Trademark 55
Jurisdiction
        United States 2,121
        World 2,102
        Canada 315
        Europe 3
Date
New (last 4 weeks) 53
2024 May (MTD) 32
2024 April 40
2024 March 31
2024 February 22
See more
IPC Class
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons 393
A61P 35/00 - Antineoplastic agents 247
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids 223
A61K 39/00 - Medicinal preparations containing antigens or antibodies 171
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 171
See more
NICE Class
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 23
41 - Education, entertainment, sporting and cultural services 16
42 - Scientific, technological and industrial services, research and design 12
16 - Paper, cardboard and goods made from these materials 3
36 - Financial, insurance and real estate services 3
See more
Status
Pending 806
Registered / In Force 3,735
  1     2     3     ...     46        Next Page

1.

SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES

      
Application Number 18263384
Status Pending
Filing Date 2022-01-31
First Publication Date 2024-05-16
Owner
  • Janssen Biotech, Inc. (USA)
  • The Broad Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Bacani, Genesis M.
  • Chai, Wenying
  • Chung, De Michael
  • Goldberg, Steven D.
  • Hirst, Gavin
  • Kaushik, Virnedar
  • Mercado-Marin, Eduardo V.
  • Raymond, Donald
  • Seierstad, Mark
  • Smith, Russel C.
  • Sundberg, Thomas
  • Tichenor, Mark S.
  • Venable, Jennifer D.
  • Wei, Jianmei
  • Xavier, Ramnik
  • Steffens, Helena C.

Abstract

Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (I), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs. Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (I), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

2.

PROTEIN PROSTHESES FOR MITOCHONDRIAL DISEASES OR CONDITIONS

      
Application Number 18516366
Status Pending
Filing Date 2023-11-21
First Publication Date 2024-05-16
Owner The General Hospital Corporation (USA)
Inventor
  • Mootha, Vamsi
  • Titov, Denis
  • Cracan, Valentin
  • Grabarek, Zenon

Abstract

The invention encompasses water-forming NADH and NADPH oxidases and the use of these enzymes to treat mammalian diseases or conditions associated with an elevated NADH/NAD+ ratio or NADPH/NADP+ ratio. Such pathologies include disorders caused by one or more defects in the mitochondrial respiratory chain, glucose metabolism disorders, cancers associated with reductive stress, and aging. The invention also provides a research tool for investigating the effect of exogenous water-forming NADH or NADPH oxidases on the metabolism of a mammalian cell, such as a human cell, and for elucidating the role of respiratory chain proteins in mitochondrial disorders.

IPC Classes  ?

  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K 14/335 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

3.

METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS

      
Application Number 18522114
Status Pending
Filing Date 2023-11-28
First Publication Date 2024-05-16
Owner
  • AMBERGEN, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Lim, Mark J.
  • Ostendorff, Heather P.
  • Rothschild, Kenneth J.
  • Bloch, Donald B.

Abstract

Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals.

IPC Classes  ?

  • G01N 33/564 - Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

4.

SYSTEMS AND METHODS FOR UNI-TO-MULTI HAIR EXTRACTION-IMPLANTATION

      
Application Number US2023037015
Publication Number 2024/102402
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Korupolu, Sandeep
  • Farinelli, William, A.
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Systems and methods for hair transplantation include and/or implement a cartridge including a plurality of slots configured to store a plurality of hair cores; an extraction unit, comprising: a first casing including a first slot configured to releasably receive the cartridge, an extracting needle, and a first actuator configured to rotate the cartridge in a state of the cartridge being received in the first slot; and an implantation unit, comprising: a second casing including a second slot configured to releasably receive the cartridge, at least one implanting needle, and a second actuator configured to rotate the cartridge in a state of the cartridge being received in the second slot.

IPC Classes  ?

5.

SYSTEMS AND METHODS FOR HAIR TRANSPLANTATION WITH SPLIT NEEDLE DEVICE

      
Application Number US2023079082
Publication Number 2024/102815
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Farinelli, William, A.
  • Korupolu, Sandeep
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Systems and methods of hair transplantation include and/or implement a device comprising a casing; an implantation unit received in the casing, the implantation unit including an implanting needle at a distal end thereof; an extraction unit received in the implantation unit, the extraction unit including an extracting needle at a distal end thereof and a first actuator portion at a proximal end thereof; and an actuation unit received in the casing and over the extraction unit, the actuation unit including a second actuator portion in cooperation with the first actuation unit and configured to selectively move the hair transplant system between a first position in which the extracting needle is at substantially the same longitudinal position as the implanting needle, and a second position in which the extracting needle is longitudinally displaced from the implanting needle in a proximal direction.

IPC Classes  ?

6.

ULTRASENSITIVE ASSAYS FOR DETECTION OF ORF1P IN BIOFLUIDS

      
Application Number US2023079148
Publication Number 2024/102852
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • THE ROCKEFELLER UNIVERSITY (USA)
  • THE JOHNS HOPKINS UNIVERSITY (USA)
Inventor
  • Taylor, Martin
  • Wu, Connie
  • Fridy, Peter, Clayton
  • Lacava, John, Paul
  • Chait, Brian, T.
  • Molloy, Kelly, Rebecca
  • Rout, Michael, Paul
  • Garden, Padric
  • Cohen, Limor
  • Walt, David, R.
  • Burns, Kathleen

Abstract

Described herein are methods and compositions for accurate detection of cancer using ultrasensitive immunoassays, e.g., digital ELISA, to detect open reading frame 1 protein (ORF1p), which is encoded by the LINE-1 retrotransposon, in biofluids.

IPC Classes  ?

  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N 30/72 - Mass spectrometers

7.

APPLICATION OF COMPUTER VISION TO ENABLE REAL-TIME DIGITAL MEASUREMENTS AND TARGETING DURING ARTHROSCOPY

      
Application Number US2023078944
Publication Number 2024/102728
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PICTUS AI LLC (USA)
Inventor
  • Tanaka, Miho
  • Varadarajan, Kartik Mangudi

Abstract

A system for performing digital measurements during a medical procedure comprises: a camera to capture image data corresponding to a treatment site; a display; an instrument placed at the treatment site, the instrument including a first section having a first dimension between a first boundary and a second boundary; and a processor configured to execute instructions to: (i) receive real-time image data from the camera, the real-time image data including a portion of the instrument, (ii) detect, in the real-time image data, a profile of the instrument, (iii) identify, on the instrument, the first boundary and the second boundary, (iv) determine a real-time measurement between a first set of points of the real-time image data, the real-time measurement being determined based in part on the first dimension, (v) generate a visualization based on the real-time measurement, and (vi) display, at the display, the visualization and the real-time image data.

IPC Classes  ?

  • A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
  • A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
  • G06N 20/20 - Ensemble learning
  • G06T 7/60 - Analysis of geometric attributes

8.

METHODS OF PREPARING NUCLEIC ACIDS FOR SEQUENCING

      
Application Number 18481021
Status Pending
Filing Date 2023-10-04
First Publication Date 2024-05-16
Owner
  • The Geneal Hospital Corporation (USA)
  • ARCHERDX, LLC (USA)
Inventor
  • Iafrate, Anthony John
  • Le, Long Phi
  • Zheng, Zongli
  • Myers, Jason
  • Stahl, Joshua

Abstract

Aspects of the technology disclosed herein relate to methods for preparing and analyzing nucleic acids. In some embodiments, methods for preparing nucleic acids for sequence analysis (e.g., using next-generation sequencing) are provided herein.

IPC Classes  ?

  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

9.

RESOLVING ABSOLUTE DEPTH IN CIRCULAR-RANGING OPTICAL COHERENCE TOMOGRAPHY

      
Application Number 17755452
Status Pending
Filing Date 2020-10-30
First Publication Date 2024-05-16
Owner The General Hospital Corporation (USA)
Inventor
  • Vakoc, Benjamin
  • Lippok, Norman

Abstract

An apparatus, including: an electromagnetic radiation source producing radiation for illuminating a sample located at an optical path depth, the electromagnetic radiation source providing the radiation to the sample to facilitate determining the optical path depth within the sample: an interferometer including: a reference arm a first portion of the radiation is delivered to, a sample arm to which a second portion of the radiation is delivered, a first optical subsystem coupled to the sample arm to interrogate the sample with the radiation delivered to the sample arm and to collect backscattered radiation from the sample, and a second optical subsystem coupled to the reference arm and the first optical subsystem to generate interference fringes between the collected backscattered radiation and the radiation delivered to the reference arm; and a data collection and processing system configured to compute the optical path depth of the sample from the received interference fringes.

IPC Classes  ?

  • G01N 21/45 - Refractivity; Phase-affecting properties, e.g. optical path length using Schlieren methods

10.

Humanized mAb107

      
Application Number 18283927
Status Pending
Filing Date 2022-03-25
First Publication Date 2024-05-16
Owner The General Hospital Corporation (USA)
Inventor Arnaout, M. Amin

Abstract

Described herein are humanized antibodies that bind to Leukocyte integrin CD11b/CD18 (CD11b, αMβ2, CR3) with enhanced affinity, and methods of use thereof.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

11.

SYSTEMS AND METHODS FOR LONG HAIR TRANSPLANTATION

      
Application Number US2023037023
Publication Number 2024/102407
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Korupolu, Sandeep
  • Farinelli, William, A.
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Hair transplant systems and methods include or use a casing; an extracting needle having a first groove extending longitudinally from a distal end of the extracting needle, the first groove including a notch; a lock disposed on the extracting needle and configured to selectively close at least a portion of the first groove; and a pin extending through a center of the casing and configured to cause the extracting needle to selectively take in or ej ect a hair follicle.

IPC Classes  ?

12.

SYSTEMS AND METHODS FOR HAIR TRANSPLANTATION BY SINGLE DEVICE WITH COUPLER

      
Application Number US2023079066
Publication Number 2024/102804
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Korupolu, Sandeep
  • Farinelli, William
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Hair transplant systems and methods include or use an extracting unit including: a first housing extending from a proximal end portion to a distal end portion, wherein the distal end portion includes an end notch defining a seat portion and a step portion, an extracting needle, and a first coupler; an implanting unit including: a second housing, an implanting needle, and a second coupler configured to be received by the first coupler; and a resilient element disposed between the extracting unit and the implanting unit to provide a biasing force to cause the hair transplant system to move between an extraction state and an implantation state. In the extraction state, the implanting unit is positioned within the seat portion of the distal end portion, and in the implantation state, the implanting unit is positioned on the step portion of the distal end portion.

IPC Classes  ?

13.

N-(N-AMINOALKYL)PHENANTHRIDIUNIUM SERIES OF CHLORIDE-SENSITIVE FLUOROPHORES AND METHODS OF USE THEREOF

      
Application Number US2023078984
Publication Number 2024/102758
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Normoyle, Kieran P.
  • Staley, Kevin

Abstract

Disclosed herein are compounds which are chloride-sensitive fluorophores and methods of manufacture and of use thereof.

IPC Classes  ?

  • C07D 221/10 - Aza-phenanthrenes
  • C08B 37/00 - Preparation of polysaccharides not provided for in groups ; Derivatives thereof

14.

SYSTEMS AND METHODS FOR SUPERVISED REMOTE IMAGING-GUIDED INTERVENTION

      
Application Number US2023036541
Publication Number 2024/097260
Status In Force
Filing Date 2023-10-31
Publication Date 2024-05-10
Owner
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Johnson, Matthew R.
  • Brattain, Laura J.
  • Telfer, Brian A.
  • Gjesteby, Lars A.
  • Werblin, Joshua S.
  • Delosa, Nancy D.
  • Samir, Anthony E.
  • Pierce, Theodore T.

Abstract

A method for remote intervention for a subject includes acquiring an image of a region of interest of the subject using an interventional device positioned on the subject and an image acquisition system. The region of interest includes a target structure and the subject is located at a first site. The method further includes analyzing the acquired image using an image analysis module to identify and label the target structure in the region of interest and transmitting the labelled image from the first site to a second site for expert review. The second site is remote from the first site. The method further includes receiving a command signal at the first site from the second site where the command signal is generated based on the expert review of the labelled image and configured to control an action of the interventional device. In some embodiments, the method may further include analyzing the acquired image to determine a pathway to the vessel that avoids critical structures.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]

15.

SUBCUTANEOUS MULTICHANNEL WIRELESS ELECTROENCEPHALOGRAPHY SYSTEM FOR CHRONIC HOME USE

      
Application Number US2023078505
Publication Number 2024/097865
Status In Force
Filing Date 2023-11-02
Publication Date 2024-05-10
Owner
  • BROWN UNIVERSITY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Nurmikko, Arto
  • Lee, Jihun
  • Lee, Ah-Hyun
  • Cash, Sydney, S.

Abstract

A system comprises one or more sensor devices for subcutaneous electroencephalography where each sensor device includes a flexible biocompatible polymer sensor strip adapted to be inserted into a cranial subdermal space and including a plurality of electrodes. The strip includes a microchip responsive to each of the electrodes and comprising a multi-channel integrated circuit system-on-chip with a wireless transceiver, a low-noise neural amplifier, a unique network address, and RF energy harvesting microcircuits. In one embodiment, the sensor strip is no more than about 1 mm wide, at least about 5 cm long, and no more than about 300 μm thick. An external transceiver is disposed on the exterior of the subject's skin near one or more sensor devices in secure wireless communication with the respective wireless transceivers comprised in the sensor devices microchips. The system is configured to communicate using a network communication protocol, such as time division multiple access or code division multiple access.

IPC Classes  ?

  • A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]

16.

METHOD AND DEVICE TO PREDICT EXERCISE PEAK VO2, CARDIOVASCULAR OUTCOMES AND FUTURE DEATH USING ECG DEEP LEARNING MODELS

      
Application Number US2023036750
Publication Number 2024/097390
Status In Force
Filing Date 2023-11-03
Publication Date 2024-05-10
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Lubitz, Steven
  • Ellinor, Patrick
  • Batra, Puneet
  • Khurshid, Shaan
  • Diamant, Nathaniel
  • Guseh, James, Sawalla
  • Friedman, Samuel

Abstract

2PEAK2 PEAK2PEAKPEAK to the first computing device associated or a device associated with the subject.

IPC Classes  ?

  • A61B 5/083 - Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
  • A61B 5/346 - Analysis of electrocardiograms
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

17.

INTRA-OCULAR OPTICAL COHERENCE TOMOGRAPHY APPARATUS AND METHOD FOR VITREORETINAL SURGERY

      
Application Number US2023078321
Publication Number 2024/097733
Status In Force
Filing Date 2023-11-01
Publication Date 2024-05-10
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • MASSACHUSETTS EYE AND EAR INFIRMARY (USA)
Inventor
  • Baldwin, Grace, Elizabeth
  • Tearney, Guillermo
  • Miller, John
  • Garcia Coleto, Andres
  • Doherty, Forrest, Nicholas
  • Romano, Francesco

Abstract

An optical probe, including; an optical fiber coupled to a moveable actuator, the moveable actuator being configured to direct light emitted from the optical fiber at a plurality of varying angles; and a relay lens distal to the moveable actuator and configured to receive light emitted from the optical fiber and direct the received light at a sample.

IPC Classes  ?

  • A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters

18.

SYSTEM AND METHOD FOR CONTROLLING AGAINST OR TREATING OF TYMPANOSTOMY TUBE INFECTIONS

      
Application Number US2023078805
Publication Number 2024/098056
Status In Force
Filing Date 2023-11-06
Publication Date 2024-05-10
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • BOSTON MEDICAL CENTER CORPORATION (USA)
Inventor
  • Dai, Tianhong
  • Pelton, Stephen, I
  • Anderson, R., Rox
  • Sabharwal, Vishakha

Abstract

Aspects of the present disclosure provide a system for preventing or treating tympanostomy tube infections. The system includes an ear tube that is configured to be placed within an ear of a subject. The ear tube has a shaft that extends from a proximal end to a distal end, and a lumen extends through the shaft. The ear tube also includes a flange extending from the shaft at the proximal end and a flange extending from the shaft at the distal end. The system further includes an optical waveguide that is configured to deliver antimicrobial light to a surface area of the ear tube while placed within the ear of the subject. The optical waveguide includes an optical fiber that is configured to deliver the antimicrobial light and a fiber collimator that is configured to guide the antimicrobial light towards the surface area of the ear tube.

IPC Classes  ?

19.

HDAC6 Inhibitors and Imaging Agents

      
Application Number 18390906
Status Pending
Filing Date 2023-12-20
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Hooker, Jacob
  • Wang, Changning
  • Strebl-Bantillo, Martin Georg
  • Rokka, Johanna Kaarina

Abstract

Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.

IPC Classes  ?

  • A61K 51/04 - Organic compounds
  • C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings

20.

METHOD AND APPARATUS FOR TIGHTENING SKIN AND OTHER TISSUES

      
Application Number 18531327
Status Pending
Filing Date 2023-12-06
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Mccormack, Michael
  • Redmond, Robert
  • Austen, Jr., William Gerald

Abstract

A system and method for treating a tissue is provided. The treatment causes a tightening or lifting of tissue. The method includes delivering a photochemical agent through a depth of the tissue to distribute the photochemical agent adjacent proteins within the tissue and irradiating the tissue with an electromagnetic irradiation at a wavelength that activates the photochemical agent, causing a protein response that brings fibers of the tissue closer together in order to one of reduce tissue laxity and tighten the tissue. A kit is provided to facilitate the method.

IPC Classes  ?

  • A61N 5/06 - Radiation therapy using light
  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser

21.

PERSONALIZED REDIRECTION AND REPROGRAMMING OF T CELLS FOR PRECISE TARGETING OF TUMORS

      
Application Number 18279848
Status Pending
Filing Date 2022-03-01
First Publication Date 2024-05-09
Owner
  • Dana-Farber Cancer Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Schwartz, Marc
  • Hacohen, Nir

Abstract

The disclosure provides methods of reprogramming polyclonal T cells to maintain long-term persistence. The disclosure further provides methods of treatment, such as adoptive T cell transfer therapies, that harness Tscms for development of tumor-reactive T cells. In some embodiments, the disclosure provides methods and compositions for positive modulation of the Tscm-producing phenotype, e.g., positive modulation of TCF7 expression. Positive modulation of TCF7 expression allows for maintenance of an increased T number of stem-like T cells capable of both self-renewal and generation of differentiated, cytolytic progeny.

IPC Classes  ?

  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/86 - Viral vectors

22.

Highly Sensitive EGFRvIII Detection

      
Application Number 18503936
Status Pending
Filing Date 2023-11-07
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Balaj, Leonora
  • Carter, Bob S.
  • Batool, Syeda Maheen

Abstract

Provided herein are methods for the detection of EGFRvIII mutation in patient samples, e.g., in tumor tissue, cerebrospinal fluid, and plasma samples, using an optimized ddPCR assay. This methods can be used, e.g., for diagnosis, monitoring tumor progression, and assessing response to therapy.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/6851 - Quantitative amplification

23.

ACTIVE QUADRATURE DEMODULATION FOR SUBSAMPLED/CIRCULAR RANGING OPTICAL COHERENCE TOMOGRAPHY

      
Application Number 18505342
Status Pending
Filing Date 2023-11-09
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Vakoc, Benjamin J.
  • Lippok, Norman

Abstract

A method including: scanning a sample over a period of time using an electro-magnetic radiation source, the period of time including a first time period and a second time period, a sample portion of the electro-magnetic radiation source being directed to the sample in a sample arm of an optical interferometric system, and a reference portion of the electro-magnetic radiation source being directed to a reference arm of the optical interferometric system; applying, using a phase modulator, a phase shift comprising a first phase shift and a second phase shift to at least one of the reference portion or the sample portion of the electro-magnetic radiation source, the first phase shift being applied during the first time period and the second phase shift being applied during the second time period, the second phase shift having a difference of 90 degrees from the first phase shift.

IPC Classes  ?

  • G01B 9/02001 - Interferometers characterised by controlling or generating intrinsic radiation properties
  • G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence

24.

Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity

      
Application Number 18507709
Status Pending
Filing Date 2023-11-13
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Kleinstiver, Benjamin

Abstract

Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome

25.

SYSTEM AND METHOD FOR DIAGNOSING CELIAC DISEASE

      
Application Number 18548951
Status Pending
Filing Date 2022-03-07
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo J.
  • Girish, Gududappanavar Nagarajappa
  • Otuya, David Odeke

Abstract

A method for identifying an intestinal disorder in a subject, including: obtaining an image of a small intestinal region of the subject; identifying a villus structure in the image; measuring at least one feature based on the identified villus structure to obtain a metric; and identifying an intestinal disorder based on the metric.

IPC Classes  ?

26.

Astrocyte Interleukin-3 Reprograms Microglia and Limits Alzheimer`s Disease

      
Application Number 18274677
Status Pending
Filing Date 2022-02-04
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Mcalpine, Cameron
  • Swirski, Filip K.
  • Tanzi, Rudolph E.

Abstract

Described herein are compositions and methods targeting IL-3 signaling for reducing Alzheimer's disease (AD)-related pathology.

IPC Classes  ?

  • A61K 38/20 - Interleukins
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

27.

FETAL ANEUPLOIDY DETECTION BY SEQUENCING

      
Application Number 18310098
Status Pending
Filing Date 2023-05-01
First Publication Date 2024-05-02
Owner
  • Verinata Health, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Stoughton, Roland
  • Kapur, Ravi
  • Cohen, Barb Ariel
  • Toner, Mehmet

Abstract

The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions.

IPC Classes  ?

  • C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

28.

CAL-T CONSTRUCTS AND USES THEREOF

      
Application Number 17769495
Status Pending
Filing Date 2020-10-16
First Publication Date 2024-05-02
Owner
  • TRUSTEES OF BOSTON UNIVERSITY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Pakyari, Mohammadreza
  • Wong, Wilson
  • Okuma, Atsushi
  • Cetrulo, Curtis

Abstract

The technology described herein is directed to compositions comprising components of multi-component CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

29.

SYSTEM AND METHOD FOR CHARACTERIZING AND TRACKING AGING, RESILIENCE, COGNITIVE DECLINE, AND DISORDERS USING BRAIN DYNAMIC BIOMARKERS

      
Application Number US2023078239
Publication Number 2024/092277
Status In Force
Filing Date 2023-10-30
Publication Date 2024-05-02
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Purdon, Patrick, L.
  • He, Mingjian
  • Das, Proloy
  • Beck, Amanda

Abstract

The present application provides systems and methods of characterizing and tracking aging, resilience, dementia, and cognitive decline using brain dynamic biomarkers. The methods and system employ advanced signal processing methods to enhance the precision and quality of information coming from the EEG to detect, characterize, or track Alzheimer's Disease (AD) and Related Dementias (ADRD). These digital markers would be relevant in all stages of AD/ AD RD spanning normal cognition, mild cognitive impairment, and AD dementia. The systems and methods include extracting one or more spectral features from EEG signal data using a plurality of state-space models.

IPC Classes  ?

  • A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
  • A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
  • A61B 5/377 - Electroencephalography [EEG] using evoked responses
  • A61B 5/384 - Recording apparatus or displays specially adapted therefor
  • G06N 3/02 - Neural networks
  • G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]

30.

SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY

      
Application Number 18324598
Status Pending
Filing Date 2023-05-26
First Publication Date 2024-05-02
Owner
  • The Children's Medical Center Corporation (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Ozcan, Umut
  • Mazitschek, Ralph
  • Guan, Dongxian

Abstract

Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.

IPC Classes  ?

  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61P 3/04 - Anorexiants; Antiobesity agents

31.

LIGHT-BASED SYSTEM AND METHOD FOR SHAPING AND TREATING HAIR

      
Application Number 18409614
Status Pending
Filing Date 2024-01-10
First Publication Date 2024-05-02
Owner The General Hospital Corporation (USA)
Inventor
  • Austen, William G.
  • Redmond, Robert
  • Mccormack, Michael

Abstract

System and methods for treating and shaping a keratin fiber are provided. A light-based system includes an activation system configured with one or more light source. The light source is configured to apply electromagnetic radiation at a target region including the keratin fiber. The light-based system applies the electromagnetic radiation to the target region to effectuate photocrosslinking with the assistance of a photosensitizer on the keratin fiber and transition the keratin fiber from a first physical state to a second physical state.

IPC Classes  ?

  • A61N 5/06 - Radiation therapy using light
  • A45D 1/04 - Curling-tongs, i.e. tongs for use when hot; Curling-irons, i.e. irons for use when hot; Accessories therefor with means for internal heating, e.g. by liquid fuel by electricity
  • A45D 2/00 - Hair-curling or hair-waving appliances

32.

A SYSTEM AND METHOD FOR MEASURING ANALGESIA AND RESPONSES TO NOXIOUS OR PAINFUL STIMULI

      
Application Number US2023078249
Publication Number 2024/092280
Status In Force
Filing Date 2023-10-30
Publication Date 2024-05-02
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Purdon, Patrick, L.
  • Gutierrez Rojas, Rodrigo
  • Das, Proloy
  • Beck, Amanda

Abstract

The present disclosure provides systems and methods for providing a quantitative assessment of pain and analgesia. The systems and methods provide, direct, objective, assessments of pain and the reduction of pain from different drugs or therapeutics. As a result, such systems and methods provide feedback for adjusting drug or therapeutics to a desired endpoint and could be used in the process of discovering or developing novel drugs or therapeutics. The system and methods include a novel state space evoked response potential (SS-ERP) model for extracting ERP signals from electroencephalography (EEG) data from a patient. The disclosed systems and methods enable the measurement of pain and pain therapeutic effects in an individualized manner.

IPC Classes  ?

  • A61B 5/369 - Electroencephalography [EEG]
  • A61B 5/372 - Analysis of electroencephalograms
  • A61B 5/375 - Electroencephalography [EEG] using biofeedback
  • A61B 5/377 - Electroencephalography [EEG] using evoked responses
  • A61M 16/01 - Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes specially adapted for anaesthetising
  • A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
  • G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data

33.

PHOTO-ECMO APPARATUS, SYSTEMS, AND METHODS

      
Application Number 18547969
Status Pending
Filing Date 2022-02-25
First Publication Date 2024-04-25
Owner The General Hospital Corporation (USA)
Inventor
  • Anderson, Richard Rox
  • Zapol, Warren
  • Fischbach, Anna
  • Farinelli, William A
  • Korupolu, Sandeep

Abstract

An apparatus for removing CO from blood, the apparatus including: a housing configured to house blood obtained from a body of a subject within an interior of the housing; a plurality of gas-permeable tubules disposed within the interior of the housing; an optical intrusion coupled to the housing and configured to project into the housing, the optical intrusion configured to transmit light into the interior of the housing; and a light source optically coupled to the optical intrusion, the light source being configured to emit light which is coupled via the optical intrusion into the interior of the housing such that the emitted light interacts with the blood from the body of the subject.

IPC Classes  ?

  • A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
  • A61M 1/16 - Dialysis systems; Artificial kidneys; Blood oxygenators with membranes

34.

Methods for Treating Autism Spectrum Disorder

      
Application Number 18274435
Status Pending
Filing Date 2022-02-02
First Publication Date 2024-04-25
Owner The General Hospital Corporation (USA)
Inventor Joshi, Gagan

Abstract

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • A61K 31/13 - Amines, e.g. amantadine
  • A61P 25/00 - Drugs for disorders of the nervous system

35.

Digital Analysis of Circulating Tumor Cells in Blood Samples

      
Application Number 18396156
Status Pending
Filing Date 2023-12-26
First Publication Date 2024-04-25
Owner The General Hospital Corporation (USA)
Inventor
  • Haber, Daniel A.
  • Kapur, Ravi
  • Toner, Mehmet
  • Maheswaran, Shyamala
  • Hong, Xin
  • Miyamoto, David Tomoaki
  • Todorova, Tanya
  • Javaid, Sarah

Abstract

This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/686 - Polymerase chain reaction [PCR]

36.

METHODS AND SYSTEMS FOR SAFE INJECTION OF DERMAL FILLER PROCEDURES

      
Application Number 18547917
Status Pending
Filing Date 2022-02-25
First Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wanner, Molly
  • Farinelli, William
  • Anderson, Richard Rox
  • Gardecki, Joseph A.
  • Beatty, Matthew J.
  • Tearney, Guillermo J.

Abstract

An injection apparatus, including: a needle configured to be inserted into a tissue; a light source to deliver light to the tissue to generate reflected light; a detector to detect the reflected light from the tissue; a processor coupled to the detector and configured to: analyze the reflected light from the tissue to identify a tissue type associated with the reflected light, and provide an output to a user based on the identified tissue type.

IPC Classes  ?

  • A61M 5/31 - Syringes - Details
  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • A61M 5/34 - Constructions for connecting the needle

37.

IRON BASED MRI PROBES

      
Application Number US2023035599
Publication Number 2024/086331
Status In Force
Filing Date 2023-10-20
Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Gale, Eric M.

Abstract

The present disclosure provides biochemically responsive Fe(II) and Fe(III) complexes useful as magnetic resonance imaging probes for diagnosis and monitoring acute and chronic inflammatory diseases affecting various organs and tissues.

IPC Classes  ?

  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • C07F 15/02 - Iron compounds
  • A61K 31/295 - Iron group metal compounds
  • A61K 33/26 - Iron; Compounds thereof

38.

IRON REPLACEMENT TREATMENTS

      
Application Number US2023076998
Publication Number 2024/086535
Status In Force
Filing Date 2023-10-16
Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Gale, Eric M.
  • Sargun, Artur
  • Babitt, Jodie
  • Fisher, Allison L.

Abstract

The present application provides compounds and methods for iron replacement therapy.

IPC Classes  ?

  • C07F 15/02 - Iron compounds
  • A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

39.

ENGINEERED CASPHI2 NUCLEASES

      
Application Number US2023077523
Publication Number 2024/086845
Status In Force
Filing Date 2023-10-23
Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Grünewald, Julian
  • Miller, Bret
  • Holtz, Eliza, Jane

Abstract

Described herein are variants of CasPhi2 nucleases with enhanced editing capabilities and methods of use thereof.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

40.

LUNG BIOREACTOR

      
Application Number 18391115
Status Pending
Filing Date 2023-12-20
First Publication Date 2024-04-18
Owner The General Hospital Corporation (USA)
Inventor Ott, Harald C.

Abstract

Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. The bioreactor comprises: an organ chamber: an ingres line connecting the organ chamber and a reservoir system and comprising an arterial line, a venous line and a tracheal line; an egress line connecting the chamber and the reservoir system, pumps in ingress and egress lines; a controller to control fluid exchange; a chamber pressure sensor connected to the organ chamber.

IPC Classes  ?

  • C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
  • A01N 1/02 - Preservation of living parts
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/36 - Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
  • A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
  • C12M 1/00 - Apparatus for enzymology or microbiology
  • C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
  • C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
  • C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors

41.

HIGH-THROUGHPUT ASSESSMENT OF EXOGENOUS POLYNUCLEOTIDE- OR POLYPEPTIDE-MEDIATED TRANSCRIPTOME PERTURBATIONS

      
Application Number 18547258
Status Pending
Filing Date 2022-02-22
First Publication Date 2024-04-18
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Al'Khafaji, Aziz
  • Keer, Frances
  • Blainey, Paul
  • Hacohen, Nir

Abstract

The present disclosure relates to methods and compositions for enhanced assessment of exogenous polynucleotide and/or polypeptide-mediated transcriptional perturbations at high throughput and single cell/droplet levels of resolution. In embodiments, nucleic acid fusions of exogenous polynucleotide(s) and associated target transcript(s) are produced within individually sequestered or discretely identifiable cells/lysates and analyzed for exogenous polynucleotide mediated perturbations across a vast population of droplets/cells within individual reactions. Kits for performance of the methods are also provided.

IPC Classes  ?

42.

SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY

      
Application Number US2023076368
Publication Number 2024/081587
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-18
Owner
  • THE CHILDREN'S MEDICAL CENTER CORPORATION (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ozcan, Umut
  • Mazitschek, Ralph
  • Guan, Dongxian

Abstract

Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.

IPC Classes  ?

  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61P 3/04 - Anorexiants; Antiobesity agents

43.

IMAGING SLOW FLOW DYNAMICS OF CEREBROSPINAL FLUID USING MAGNETIC RESONANCE IMAGING

      
Application Number US2023076679
Publication Number 2024/081779
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Dong, Zijing
  • Wang, Fuyixue
  • Wald, Lawrence, L.
  • Lewis, Laura
  • Polimeni, Jonathan

Abstract

Magnetic resonance imaging (MRI) is used to image the slow flow of cerebrospinal fluid (CSF) in subarachnoid and perivascular spaces, amongst other regions of the brain and central nervous system. The slow CSF flow imaging can be provided by using low velocity' encoding (VENC) and an efficient data acquisition. Tailored image processing can be used to further improve the accuracy, specificity, and visualization of CSF flow dynamics.

IPC Classes  ?

  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • G16H 30/00 - ICT specially adapted for the handling or processing of medical images

44.

SYSTEM AND METHOD FOR CONTROL OF IONIZING RADIATION DOSE IN MEDICAL APPLICATIONS USING SYNTHETIC LOCALIZERS

      
Application Number US2023076749
Publication Number 2024/081822
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Yang, Kai
  • Sharma, Amita
  • Gupta, Rajiv
  • Marschall, Theodore
  • Savage, Cristy
  • Flynn, Karen
  • Redel, Travis
  • Mcnulty, Frederick

Abstract

Methods, system, and non-transitory media are provided for tube-current-modulation (TCM) calculation in computed tomography (CT) imaging. The radiation dose exposure is adjusted by identifying dose varying anatomical markers such as arms or removable objects that are not consistently positioned between localizer and actual scanning. Provided herein are means of reducing the effect of those anatomical markers on the TCM calculation by generating a synthetic localizer from an acquired localizer of a patient wherein the anatomical marker has been modified to match the actual scanning status. Modification of the dose-varying anatomical marker may include changing the position from an arms-down to arms up position or complete image signal removal of the arms or other markers from the localizer.

IPC Classes  ?

  • A61B 6/03 - Computerised tomographs
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G06T 7/00 - Image analysis

45.

COMPOSITIONS AND METHODS USING REELIN IN ALZHEIMER'S DISEASE

      
Application Number US2023076914
Publication Number 2024/081934
Status In Force
Filing Date 2023-10-13
Publication Date 2024-04-18
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • MASSACHUSETTS EYE AND EAR INFIRMARY (USA)
  • BANNER HEALTH (USA)
Inventor
  • Quiroz-Gaviria, Yakeel Tatiana
  • Arboleda-Velasquez, Joseph F.
  • Lopera, Francisco
  • Reiman, Eric

Abstract

Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C12N 15/86 - Viral vectors
  • C12N 9/22 - Ribonucleases
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

46.

LOCALIZATION AND TARGETING OF SMALL PULMONARY LESIONS

      
Application Number US2023076621
Publication Number 2024/081745
Status In Force
Filing Date 2023-10-11
Publication Date 2024-04-18
Owner
  • CANON U.S.A., INC. (USA)
  • THE BRIGHAM AND WOMEN'S HOSPITAL INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Beqari, Jorind
  • Hurd, Jacob
  • Masaki, Fumitaro
  • King, Franklin
  • Hata, Nobuhiko
  • Colson, Yolonda Lorig

Abstract

One or more devices, systems, methods, and storage mediums for performing robotic control and/or for performing localization and lesion targeting are provided herein. Examples of such control, localization and lesion targeting include, but are not limited to, correction of one or more sections or portions of a continuum robot as the continuum robot is moved and performing localization and lesion targeting in a bronchial pathway using a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for bronchial applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing, imaging, and lesion targeting efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.

IPC Classes  ?

  • A61B 34/32 - Surgical robots operating autonomously
  • A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
  • A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
  • A61B 34/30 - Surgical robots
  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

47.

ENGINEERED BIFUNCTIONAL RECEPTORS AND USES THEREOF

      
Application Number US2023076534
Publication Number 2024/081690
Status In Force
Filing Date 2023-10-11
Publication Date 2024-04-18
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
Inventor
  • Jan, Max
  • Ebert, Benjamin
  • Maus, Marcela
  • Manguso, Robert
  • Mears, Kepler
  • Lane, Isabel

Abstract

Described in several example embodiments herein are engineered bifunctional receptors that can include an E3 ligase binding domain and a target binding domain operatively coupled to the E3 ligase binding domain. In some embodiments, the engineered bifunctional receptors are capable of targeted degradation of a target protein. Also described in several example embodiments herein are compositions, formulations, and cells that can include or generate the engineered bifunctional receptors and uses thereof.

IPC Classes  ?

  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

48.

METHOD AND SYSTEM FOR MOTION-ROBUST SUPER-RESOLUTION MAGNETIC RESONANCE IMAGING

      
Application Number US2023076639
Publication Number 2024/081753
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Dong, Zijing
  • Wang, Fuyixue
  • Polimeni, Jonathan
  • Wald, Lawrence, L.

Abstract

The present disclosure provides a method for generating MRI images of a subject. The method includes accessing MRI images of the subject that have a first resolution, where each of the MRI images was acquired with a selected sampling pattern. The method further includes estimating motion between the MRI images to determine a motion transformation that corresponds to motion of the subject between the MRI images. The method further includes applying a model-based super-resolution reconstruction to the MRI images. The reconstruction accounts for the motion transformation and generates an image of the subject within the image volume that has a second resolution greater than the first resolution.

IPC Classes  ?

  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • G16H 30/00 - ICT specially adapted for the handling or processing of medical images

49.

METHODS FOR ACCELERATED TIME-RESOLVED MULTI-ECHO MAGNETIC RESONANCE IMAGING BY AUGMENTING TEMPORAL CORRELATION

      
Application Number US2023076677
Publication Number 2024/081777
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wang, Fuyixue
  • Dong, Zijing
  • Polimeni, Jonathan
  • Wald, Lawrence, L.

Abstract

Accelerated time-resolved multi-echo magnetic resonance imaging (MRI) uses augmenting of the temporal correlation across echoes, for example, by applying gradient blips that sample the spatiotemporal space in a new trajectory to reduce dead time and echo spacing. Additionally or alternatively, acceleration may be achieved by optimization of the encoding pattern to reduce temporal distance and/or using a spatiotemporal partial Fourier acquisition.

IPC Classes  ?

  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • G16H 30/00 - ICT specially adapted for the handling or processing of medical images

50.

LIBRARY-SCALE METHODS FOR POLYPEPTIDE FUNCTIONAL ANALYSIS

      
Application Number US2023076724
Publication Number 2024/081807
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Dekosky, Brandon
  • Jin, Shuyan
  • Johnson, Shelbe Marie
  • Gutierrez, Matias F.

Abstract

Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen/immune receptor interactions, in a single-cell format.

IPC Classes  ?

  • C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

51.

IMMUNOCAPTURE METHODS TO ENRICH FOR ENGINEERED EXTRACELLULAR VESICLES

      
Application Number US2023076828
Publication Number 2024/081876
Status In Force
Filing Date 2023-10-13
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Breyne, Koen
  • Breakefield, Xandra O.

Abstract

Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineered to display their surface an antigenic tag for fast and efficient EV isolation by immunocapture and a fluorescent protein in the internal space of the EV. Cargo was loaded into the lumen of the EVs by fusing the cargo with an antibody or nanobody that has an affinity for the fluorescent protein of the internal space. To prevent potential antigenicity of the EVs, a TEV cleavage site was included allowing the removal of exposed antigenic tag from immunocaptured EVs, while preserving their luminal cargo.

IPC Classes  ?

  • A61K 9/127 - Liposomes
  • A61K 38/46 - Hydrolases (3)
  • A61K 38/53 - Ligases (6)
  • B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
  • C07K 19/00 - Hybrid peptides
  • C12N 9/22 - Ribonucleases
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

52.

COVALENT COMPOUNDS AND USES THEREOF

      
Application Number US2023076610
Publication Number 2024/081739
Status In Force
Filing Date 2023-10-11
Publication Date 2024-04-18
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
  • Iafrate, Anthony John
  • Bar-Peled, Liron
  • Yang, Diane
  • Liau, Brian
  • Harry, Stefan

Abstract

The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound and methods of identifying one or more targets using such a compound.

IPC Classes  ?

  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
  • A61K 31/03 - Halogenated hydrocarbons carbocyclic aromatic
  • A61K 31/035 - Halogenated hydrocarbons having aliphatic unsaturation
  • C07C 233/07 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

53.

SYSTEM AND METHOD FOR MULTIPHOTON PARALLEL TRANSMIT EXCITATION FOR MRI

      
Application Number US2023076709
Publication Number 2024/081799
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wald, Lawrence, L.
  • Drago, John
  • Guerin, Bastien

Abstract

A method for generating a magnetic resonance image of a subject using a magnetic resonance imaging (MRI) system includes receiving, using the MRI system, at least one parameter for a multiphoton parallel transmit excitation comprising a multiphoton excitation pulse configured to correct spatial inhomogeneities and performing, using the MRI system, a pulse sequence comprising the multiphoton parallel transmit excitation to acquire data from the subject. The multi photon excitation pulse of the multi photon parallel transmit excitation is performed using a radio frequency (RF) coil and a set of one or more shim coils of the MRI system. The method further includes generating, using a processor, an image of the subject using the acquired MR data. In some embodiments, the multiphoton excitation pulse includes an off-resonance RF excitation pulse performed using the RF coil and a plurality of low-frequency excitation pulses performed using the set of one or more shim coils. The plurality of low-frequency excitation pulses are performed simultaneously with the off-resonance RF excitation pulse.

IPC Classes  ?

  • G01R 33/38 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
  • G01R 33/3875 - Compensation of inhomogeneities using correction coil assemblies, e.g. active shimming
  • G01R 33/48 - NMR imaging systems
  • G01R 33/54 - Signal processing systems, e.g. using pulse sequences
  • G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
  • G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

54.

PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

      
Application Number 18468384
Status Pending
Filing Date 2023-09-15
First Publication Date 2024-04-11
Owner
  • The Broad Institute, Inc. (USA)
  • Dana-Farber Cancer Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Chapuy, Bjoern
  • Stewart, Donald
  • Wood, Tim
  • Shipp, Margaret
  • Getz, Gad
  • Murakami, Mark
  • Lawton, Lee
  • Dunford, Andrew
  • Wienand, Kirsty

Abstract

The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/6869 - Methods for sequencing
  • G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
  • G16B 40/20 - Supervised data analysis

55.

SYSTEM AND METHOD FOR NON-INVASIVE, INTRACRANIAL BRAIN MOTION MONITORING

      
Application Number 18538583
Status Pending
Filing Date 2023-12-13
First Publication Date 2024-04-11
Owner The General Hospital Corporation (USA)
Inventor
  • Zhang, Quan
  • Strangman, Gary

Abstract

A system and a method is provided for assessing motion of a biological tissue of a subject including one or more superficial biological layers and a targeted biological layer. A perturbation unit provide an optical perturbation to the one or more superficial biological layers. An optical signal generator transmits optical signals at one or more near-infrared wavelengths. An optical signal receiver acquires a set of optical signal data preceding, during, or following the optical perturbation at a first acquisition time relative to the optical perturbation. A signal processor determines, using the set of optical signal data, a set of optical characteristics and separates, using the set of optical characteristics, a target optical signal. The signal processor generates a report indicative of a movement of the targeted biological tissue within the subject. The movement of the targeted biological layer is calculated using the target optical signal.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters

56.

MINIMALLY INVASIVE DEVICE FOR NERVE IDENTIFICATION, STIMULATION, AND MANIPULATION

      
Application Number US2023076364
Publication Number 2024/077294
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Gfrerer, Lisa
  • Srinivasan, Shriya, S.
  • Austen, Jr., William, G.

Abstract

Systems and methods for an insertable medical device are described. The device comprises a device body configured to be insertable into a subject; proximal and distal openings; a cavity extending through the device body and in communication with the proximal opening and the distal opening, the cavity and the proximal opening being dimensioned to receive an instrument therein; a plurality of electrically conductive pads configured to be positioned a predetermined location relative to the proximal and distal openings, and configured to sense an electrical characteristic of the subject; an I/O device configured to: output signal data from the electrically conductive pads to a processing device operating a ML algorithm, the signal data including data corresponding to the electrical characteristic of the subject, and receive response data generated by the ML algorithm indicating a tissue type proximate respective electrically conductive pads based on an analysis of the signal data.

IPC Classes  ?

  • A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
  • A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

57.

METHOD AND APPARATUS FOR TISSUE GRAFTING AND COPYING

      
Application Number 18483848
Status Pending
Filing Date 2023-10-10
First Publication Date 2024-04-11
Owner The General Hospital Corporation (USA)
Inventor
  • Anderson, Richard Rox
  • Farinelli, William A.
  • Franco, Walfre
  • Tam, Joshua
  • Sakamoto, Fernanda H.
  • Doukas, Apostolos G.
  • Purschke, Martin
  • Yao, Min

Abstract

Exemplary embodiments of apparatus and method for obtaining one or more portions of biological tissue (“micrografts”) to form grafts are provided. For example, a hollow tube can be inserted into tissue at a donor site, and a pin provided within the tube can facilitate controlled removal of the micrograft from the tube. Micrografts can be harvested and directly implanted into an overlying biocompatible matrix through coordinated motion of the tube and pin. A needle can be provided around the tube to facilitate a direct implantation of a micrograft into a remote recipient site or matrix. The exemplary apparatus can include a plurality of such tubes and pins for simultaneous harvesting and/or implanting of a plurality of micrografts. The harvested micrografts can have a small dimension, e.g., less than about 1 mm, which can promote healing of the donor site and/or viability of the harvested tissue.

IPC Classes  ?

58.

SYSTEMS AND METHODS FOR RADIATION ONCOLOGY WORKFLOW MANAGEMENT

      
Application Number US2023076210
Publication Number 2024/077222
Status In Force
Filing Date 2023-10-06
Publication Date 2024-04-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Wolfgang, John

Abstract

A radiation oncology workflow management system is provided. The system may include interactive graphical interface and a particularly programmed processor, thereby to perform operations including displaying a window containing a user interface (UI) environment on a computer screen, parsing an input received from a user via the UI environment, thereby to determine which of a plurality of atomic application functions is indicated by the input, automatically interacting with an atomic application associated with the atomic application function determined to be indicated by the input, and automatically displaying information received from the atomic application via the UI environment.

IPC Classes  ?

  • G06Q 10/10 - Office automation; Time management
  • G06Q 10/0631 - Resource planning, allocation, distributing or scheduling for enterprises or organisations
  • G06Q 10/0633 - Workflow analysis
  • G06Q 50/22 - Social work
  • G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
  • G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
  • G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

59.

METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OF PEPTIDE-MHC TARGETING BINDING PROTEINS

      
Application Number US2023076267
Publication Number 2024/077256
Status In Force
Filing Date 2023-10-06
Publication Date 2024-04-11
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
  • Hacohen, Nir
  • Liu, Bingxu
  • Bakalar, Matthew
  • Chen, Xun

Abstract

The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR T cells capable of binding to peptides bound to specific MHC alleles.

IPC Classes  ?

  • C07K 14/725 - T-cell receptors
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

60.

METHODS FOR INHIBITING RAS

      
Application Number 18479500
Status Pending
Filing Date 2023-10-02
First Publication Date 2024-04-04
Owner
  • The General Hospital Corporation (USA)
  • Revolution Medicines, Inc. (USA)
Inventor
  • Corcoran, Ryan B.
  • Nichols, Robert J.

Abstract

The disclosure features methods for inhibiting RAS proteins, e.g., RAS proteins that have acquired resistance to one or more RAS inhibitors. The disclosure also methods for the treatment of cancer.

IPC Classes  ?

  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 35/00 - Antineoplastic agents

61.

INTERPRETATION OF INTRAOPERATIVE SENSOR DATA USING CONCEPT GRAPH NEURAL NETWORKS

      
Application Number 18550367
Status Pending
Filing Date 2022-03-28
First Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Meireles, Ozanan R.
  • Ban, Yutong
  • Hashimoto, Daniel A.
  • Rosman, Guy
  • Ward, Thomas
  • Rus, Daniela

Abstract

Systems and methods are provided for generating a statistical parameter representing a state of a surgical procedure from sensor data. Sensor data representing a time period. is received from a sensor. Numerical features representing the time period are generated from the sensor data. Each of a plurality of long short term memory units are updated according to the plurality of numerical features via a message passing process. The long short term memory units are connected to form a graph, with a first set of the long short term memory units representing a plurality of nodes of the graph and a second set of the long short term memory units representing a plurality of hyperedges of the graph. A statistical parameter representing a state of the surgical procedure for the time period is derived from an output of one of the long short term memory units and provided to a user.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
  • G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

62.

ARTIFICIAL INTELLIGENCE ENABLED DISCRIMINATION OF DISEASE AND DISEASE ETIOLOGY

      
Application Number US2023033803
Publication Number 2024/072849
Status In Force
Filing Date 2023-09-27
Publication Date 2024-04-04
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Lubitz, Steven
  • Batra, Puneet
  • Haimovich, Julian
  • Diamant, Nathaniel
  • Khurshid, Shaan
  • Ho, Jennifer

Abstract

The subject matter disclosed herein relates using waveform data of a subject to detect one or more diseases or disease etiologies. Particular examples relate to providing a system, a computer-implemented method, and a computer program product to waveform data to detect and differentiate particular diseases and disease etiologies with machine learning models.

IPC Classes  ?

  • A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/341 - Vectorcardiography [VCG]
  • A61B 5/346 - Analysis of electrocardiograms
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
  • G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

63.

Minimally Invasive Devices and Methods for Measuring Intestinal Potential Difference

      
Application Number 18263558
Status Pending
Filing Date 2022-01-31
First Publication Date 2024-04-04
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo
  • Otuya, David Odeke
  • Farrokhi, Hamid
  • Shi, Serena Qinyun Z
  • Silva, Sarah Lynn
  • Dong, Jing

Abstract

A system for determining intestinal potential difference. The system includes a measurement probe including a measurement tube having a measurement lumen which houses a measurement electrode therein, a measurement fluid delivery system in fluid communication with the measurement lumen, the measurement fluid delivery system being configured to deliver an electrically-conductive fluid into the measurement lumen such that the electrically-conductive fluid is electrically coupled to the measurement electrode, and the measurement lumen including an outlet at a distal end thereof through which the electrically-conductive fluid exits the measurement lumen and contacts an intestinal tissue of a subject to provide electrical coupling between the measurement electrode and the intestinal tissue; a controller coupled to the measurement electrode configured to measure a potential difference between tire measurement electrode and a reference electrode electrically coupled to the subject.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
  • A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
  • A61B 5/262 - Needle electrodes
  • A61B 5/265 - Bioelectric electrodes therefor characterised by the electrode materials containing silver or silver chloride
  • A61B 5/301 - Input circuits therefor providing electrical separation, e.g. by using isolating transformers or optocouplers

64.

MODULATION OF A PATHOGENIC PHENOTYPE IN TH1 CELLS

      
Application Number 18273579
Status Pending
Filing Date 2022-01-21
First Publication Date 2024-04-04
Owner
  • The Brigham and Women's Hospital, Inc. (USA)
  • The Broad Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
  • The Regents of the University of California (USA)
Inventor
  • Kuchroo, Vijay K.
  • Xavier, Ramnik
  • Pawlak, Mathias
  • Detomaso, David
  • Yosef, Nir

Abstract

The subject matter disclosed herein is generally directed to pathogenic Th1 cells whose phenotype is dependent on IL-23R signaling. Th1 cell specific therapeutic targets and gene programs are disclosed herein. In particular, inhibition of CD160 reduces Th1 cell pathogenicity.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 37/02 - Immunomodulators
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12N 9/22 - Ribonucleases

65.

FC-ENHANCED ANTIBODIES FOR PREVENTION AND TREATMENT OF EBOLA VIRUS INFECTION

      
Application Number 18274641
Status Pending
Filing Date 2022-02-01
First Publication Date 2024-04-04
Owner The General Hospital Corporation (USA)
Inventor
  • Alter, Galit
  • Lu, Richard

Abstract

Described herein are Fe-enhanced antibodies and methods of use thereof. Also described are Fe-enhanced antibodies to treat Ebola virus infection.

IPC Classes  ?

  • C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
  • A61P 31/14 - Antivirals for RNA viruses

66.

GASTRORETENTIVE ARTICLES FOR ALCOHOL SENSING

      
Application Number 18541818
Status Pending
Filing Date 2023-12-15
First Publication Date 2024-04-04
Owner
  • Massachusetts Institute of Technology (USA)
  • The Brigham and Women's Hospital, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Langer, Robert S.
  • Traverso, Carlo Giovanni
  • Verma, Malvika
  • Eweje, Feyisope
  • Steiger, Christoph Winfried Johannes
  • Li, Junwei
  • Phan, Nhi
  • Huang, Hen-Wei
  • Chu, Jacqueline
  • Salama, John Ashraf Fou

Abstract

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

IPC Classes  ?

  • A61B 5/07 - Endoradiosondes
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

67.

MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (OHSV) AND METHODS OF USE THEREOF

      
Application Number US2023075127
Publication Number 2024/073416
Status In Force
Filing Date 2023-09-26
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Martuza, Robert L.
  • Rabkin, Samuel D.
  • Saha, Dipongkor
  • Jahan, Nusrat

Abstract

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer/promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

68.

ADMINISTRATION OF GLUTATHIONE TRISULFIDE TO AMELIORATE PERIPHERAL NEUROPATHY

      
Application Number US2023075131
Publication Number 2024/073420
Status In Force
Filing Date 2023-09-26
Publication Date 2024-04-04
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • KYOWA HAKKO BIO CO., LTD. (Japan)
Inventor
  • Ichinose, Fumito
  • Ezaka, Mariko
  • Ohshima, Etsuo

Abstract

Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.

IPC Classes  ?

  • A61K 38/06 - Tripeptides
  • C07K 5/02 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
  • A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

69.

4-1BBL AND IL-12 THERAPY FOR TREATMENT OF GLIOBLASTOMA

      
Application Number US2023075225
Publication Number 2024/073483
Status In Force
Filing Date 2023-09-27
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Breyne, Koen
  • Breakefield, Xandra O.
  • Mempel, Thorsten R.

Abstract

Provided herein are methods of treating glioblastoma including administering to a subject having glioblastoma a therapeutically effective amount of a pharmaceutical composition comprising 4-1BBL, optionally in combination with recombinant IL-12. The 4-1BBL can be provided to the subject via an adeno-associated virus, for example AAV-F, and the IL-12 can be provided by intratumoral injection.

70.

PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION

      
Application Number US2023075230
Publication Number 2024/073486
Status In Force
Filing Date 2023-09-27
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wu, Xu
  • Hu, Lu

Abstract

The present disclosure relates to compounds of Formula I and methods comprising the use of these compounds to identify ligandable fatty acylation sites.

IPC Classes  ?

  • G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
  • G01N 33/483 - Physical analysis of biological material
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

71.

SYSTEM AND METHOD FOR DETERMINING PERFUSED TISSUE VIABILITY

      
Application Number US2023075328
Publication Number 2024/073540
Status In Force
Filing Date 2023-09-28
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Evans, Conor, L.
  • Berkane, Yanis
  • Uygun, Mustafa, Korkut
  • Cascales Sandoval, Juan
  • Lellouch, Alexandre, G.
  • Rousakis, Emmanouil

Abstract

The disclosure provides perfusion systems and methods for continuous or intermittent perfusion to monitor and extend the viability of tissue for transplants. Intermittent perfusion involves generating perfusion cycles which alternate between baseline and high oxygen gas partial pressure in the circulating perfusate. The system comprises a perfusion fluid source and an inflow conduit in fluid communication with the perfusion fluid source and a tissue sample, wherein the inflow conduit is configured to deliver perfusion fluid to the tissue sample. The system further comprises an outflow conduit in fluid communication with the tissue sample, wherein the outflow conduit is configured to carry perfusion fluid away from the tissue sample. A first gas sensor is in fluid communication with the inflow-conduit and measures a. concentration of a gas in perfusion fluid, in the inflow conduit, and a second gas sensor is in contact with the tissue sample and measures a concentration of a gas in the sample.

IPC Classes  ?

72.

GENE THERAPY FOR GENETIC AND ACQUIRED VASCULOPATHIES

      
Application Number US2023075589
Publication Number 2024/073715
Status In Force
Filing Date 2023-09-29
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Musolino, Patricia L.
  • Lindsay, Mark Evan
  • Kleinstiver, Benjamin P
  • Maguire, Casey A.
  • Chung, David Young
  • Cardenas, Christian Lacks Lino
  • Malhotra, Rajeev

Abstract

Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant alleles or a Cas nuclease that knocks out the mutant allele.

IPC Classes  ?

  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

73.

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES

      
Application Number 18273395
Status Pending
Filing Date 2022-01-21
First Publication Date 2024-03-28
Owner The General Hospital Corporation (USA)
Inventor Faustman, Denise L.

Abstract

The disclosure features antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the downstream signaling of TNFR superfamily members. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, infectious diseases, autoimmune disorders, obesity, type 2 diabetes, neurological disorders, and osteoporosis.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

74.

AN ENZYMATIC SYSTEM FOR PRECISE CELL TARGETING

      
Application Number US2023074780
Publication Number 2024/064818
Status In Force
Filing Date 2023-09-21
Publication Date 2024-03-28
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Holden, Rebecca
  • Bakalar, Matt
  • Hacohen, Nir

Abstract

The disclosure provides compositions and methods for enzyme-mediated precise cell targeting.

IPC Classes  ?

  • C12N 9/88 - Lyases (4.)
  • C12Q 1/527 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase

75.

METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

      
Application Number US2023074708
Publication Number 2024/064766
Status In Force
Filing Date 2023-09-20
Publication Date 2024-03-28
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
Inventor
  • Letai, Anthony
  • Knisbacher, Binyamin
  • Parvin, Salma
  • Getz, Gad
  • Wu, Catherine

Abstract

As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.

IPC Classes  ?

  • G01N 33/483 - Physical analysis of biological material
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

76.

METHODS AND COMPOSITION FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER

      
Application Number 18270611
Status Pending
Filing Date 2021-12-30
First Publication Date 2024-03-28
Owner The General Hospital Corporation (USA)
Inventor Kong, Xue-Jun

Abstract

Disclosed herein are methods and compositions useful for the treatment of Autism Spectrum Disorder (ASD). The methods and compositions include combination therapy with probiotics and oxytocin (OXT), resulting in a therapeutic synergy that exerts beneficial effects on ASD symptoms. The methods and compositions provide improvements in several measurable parameters including but not limited to: measured clinical index for ASD core symptoms, gut microbiome profile, and levels of OXT and inflammatory markers in the blood.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 38/095 - Oxytocins; Vasopressins; Related peptides
  • A61P 25/00 - Drugs for disorders of the nervous system

77.

T CELL-DIRECTED ANTI-CANCER VACCINES AGAINST COMMENSAL VIRUSES FOR TREATING MUCOSAL CARCINOMAS

      
Application Number 18273466
Status Pending
Filing Date 2022-01-21
First Publication Date 2024-03-28
Owner The General Hospital Corporation (USA)
Inventor Demehri, Shadmehr

Abstract

Immune-based approaches to treat and reduce the risk of cancer of mucosal tissues by boosting T cell immunity against commensal HPVs.

IPC Classes  ?

  • A61K 39/12 - Viral antigens
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

78.

MICROMOTOR AND OPTICAL ARRANGEMENT FOR FAST CIRCULAR SCANNING OF LIGHT BEAMS IN SMALL DIAMETER FLEXIBLE CATHETERS

      
Application Number US2023074596
Publication Number 2024/064689
Status In Force
Filing Date 2023-09-19
Publication Date 2024-03-28
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Bouma, Brett, E.
  • Shishkov, Milen
  • Uribe-Patarroyo, Néstor
  • Schmidt, Ginger

Abstract

The disclosure presents a shaftless, brushless motor for rotating any optical or sensing element (e.g., a lens or mirror) at a distal end of a waveguide that also delivers electromagnetic radiation (e.g., light). Herein, the waveguide itself functions as the axle on which rotating components rotate, thereby avoiding blind spots and overcoming limitations in existing "micromotors". The shaftless, distally driven motor significantly reduces motor size, while extremely small inertial loads and bearing sizes allow for high pitch cylindrical scanning with longitudinal velocity uniformity.

IPC Classes  ?

  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • G02B 6/00 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings

79.

METHOD AND APPARATUS FOR MODULATING SIGNALS OF LUMINESCENT POLYMER/DYE FORMULATIONS USING LIGHT SCATTERING PARTICLES

      
Application Number US2023074688
Publication Number 2024/064750
Status In Force
Filing Date 2023-09-20
Publication Date 2024-03-28
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • 3M INNOVATIVE PROPERTIES COMPANY (USA)
Inventor
  • Müller, Matthias
  • Evans, Conor, L.
  • Rousakis, Emmanouil
  • Cascales Sandoval, Juan, Pedro
  • Bjork, Jason
  • Muyres, Dawn
  • Wilken-Resman, Elias
  • Demirgöz, Döne
  • Apiou, Gabriela

Abstract

A sensing system and method for sensing an analyte. The sensing system includes; a sensing material having one or more layers, the sensing material including; a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix. The sensing method includes: providing a sensing material including one or more layers, the sensing material including a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix, the light emitting material being sensitive to an analyte; exposing the sensing system to the analyte; and measuring a change in a light emission from the light emitting material based on exposing the sensing system to the analyte.

IPC Classes  ?

  • G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection

80.

Image-seq: A New Technology for Spatially-Resolved Single-Cell RNA Sequencing

      
Application Number 18363298
Status Pending
Filing Date 2023-08-01
First Publication Date 2024-03-21
Owner The General Hospital Corporation (USA)
Inventor
  • Haase, Christa
  • Richter, Dmitry
  • Lin, Charles

Abstract

A system and method for image-guided cell isolation from a region of interest of a subject is disclosed. The system and method include imaging the subject using optical microscopy to identify the region of interest in a target anatomy, inserting a micropipette into the region of interest under guidance of the optical microscopy, and aspirating at least one cell of a target population of cells in the region of interest under guidance of the optical microscopy. The method further includes analyzing the at least one cell aspirated from the region of interest.

IPC Classes  ?

  • C12Q 1/6869 - Methods for sequencing
  • A61B 10/02 - Instruments for taking cell samples or for biopsy
  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
  • A61B 90/20 - Surgical microscopes characterised by non-optical aspects

81.

COMPOUNDS FOR TAU PROTEIN DEGRADATION

      
Application Number 18200950
Status Pending
Filing Date 2023-05-23
First Publication Date 2024-03-21
Owner
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL (USA)
Inventor
  • Gray, Nathanael S.
  • Haggarty, Stephen J.
  • Cai, Quan
  • Zhang, Tinghu
  • Telo Baptista Lima Da Silva, Maria Catarina
  • Ferguson, Fleur M.

Abstract

Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

IPC Classes  ?

  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 38/05 - Dipeptides
  • A61K 51/04 - Organic compounds
  • C07D 471/04 - Ortho-condensed systems
  • C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
  • G01N 33/534 - Production of labelled immunochemicals with radioactive label
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

82.

GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE

      
Application Number 18351169
Status Pending
Filing Date 2023-07-12
First Publication Date 2024-03-21
Owner The General Hospital Corporation (USA)
Inventor Grinspoon, Steven K.

Abstract

The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.

IPC Classes  ?

  • A61K 38/25 - Growth hormone-releasing factor [GH-RF] (Somatoliberin)
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

83.

Systemic Delivery of Polypeptides

      
Application Number 18325332
Status Pending
Filing Date 2023-05-30
First Publication Date 2024-03-21
Owner
  • President and Fellows of Harvard College (USA)
  • Massachusetts Institute of Technology (USA)
  • The Brigham and Women's Hospital, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Milanova, Denitsa M.
  • Church, George M.
  • Davidsohn, Noah
  • Schoellhammer, Carl
  • Langer, Robert S.
  • Mandinova, Anna I.
  • Traverso, Carlo Giovanni

Abstract

A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61N 7/00 - Ultrasound therapy
  • C12N 15/86 - Viral vectors

84.

COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION

      
Application Number 18351198
Status Pending
Filing Date 2023-07-12
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Ruvkun, Gary
  • Govindan, J. Amaranath
  • Jayamani, Elamparithi

Abstract

Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and/or peroxisomal function.

IPC Classes  ?

  • A61K 35/74 - Bacteria
  • A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
  • A23L 2/52 - Adding ingredients
  • A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C12N 1/20 - Bacteria; Culture media therefor
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

85.

ANTI-BMP9 ANTIBODIES AND METHODS OF USE THEREOF

      
Application Number 18326335
Status Pending
Filing Date 2023-05-31
First Publication Date 2024-03-14
Owner
  • Pfizer Inc. (USA)
  • The Brigham and Women's Hospital, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Yu, Paul B.
  • Apgar, James Reasoner
  • Benard, Susan Adam
  • Berasi, Stephen Peter
  • Huard, Christine
  • Kovalenko, Oleg Victorovich
  • Mosyak, Lidia
  • Tang, Xianchun
  • Tumelty, Kathleen Elisabeth
  • Troncone, Luca
  • Zhong, Ying

Abstract

Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

IPC Classes  ?

  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61P 9/12 - Antihypertensives

86.

SUPRAMOLECULAR HYBRID HYDROGELS FOR BURN AND WOUND DRESSINGS

      
Application Number US2023032178
Publication Number 2024/054562
Status In Force
Filing Date 2023-09-07
Publication Date 2024-03-14
Owner
  • TRUSTEES OF TUFTS COLLEGE (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Asatekin Alexiou, Ayse
  • Gokaltun, Ayse, Aslihan
  • Usta, Osman, Berk
  • Mazzaferro, Luca
  • Stafford, Zosia

Abstract

Disclosed are supramolecular hybrid hydrogels (SHH), wound dressings, comprising supramolecular hybrid hydrogels; and methods of treating wounds, including burns.

IPC Classes  ?

  • A61F 13/00 - Bandages or dressings; Absorbent pads
  • A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages

87.

RETT SYNDROME THERAPY

      
Application Number GB2023052315
Publication Number 2024/052681
Status In Force
Filing Date 2023-09-07
Publication Date 2024-03-14
Owner
  • THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (United Kingdom)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Kleinstiver, Benjamin
  • Guy, Jacqueline
  • Bird, Adrian

Abstract

The present disclosure relates to compositions for use in the treatment of a class of Rett syndrome mutations, namely C-terminal deletions, comprising a base editor to alter a stop codon in a mutant MECP2 gene. This alteration does not return the gene to its wild-type (WT) form, but re-establishes normal levels of a version which is functionally equivalent to a wild¬ type version of the MeCP2 protein.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 9/22 - Ribonucleases
  • C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

88.

SYSTEM FOR MEASURING AND MONITORING BLOOD PRESSURE

      
Application Number 18388117
Status Pending
Filing Date 2023-11-08
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Zhang, Quan
  • Zhang, Yuanting

Abstract

A system and method for measuring and monitoring blood pressure is provided. The system includes a wearable device and a tonometry device coupled to the wearable device. The Tonometry device is configured to compress a superficial temporal artery (STA) of a user. A sensor pad is attached to the wearable device adjacent the tonometry device. A blood pressure sensor is integrated within the sensor pad for continuous, unobtrusive blood pressure monitoring.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/021 - Measuring pressure in heart or blood vessels
  • A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthaldynamometers
  • A61B 5/026 - Measuring blood flow
  • A61B 5/33 - Heart-related electrical modalities, e.g. electrocardiography [ECG] specially adapted for cooperation with other devices

89.

GENETIC VARIANTS ASSOCIATED WITH LOCAL FAT DEPOSITION TRAITS FOR THE TREATMENT OF HERITABLE METABOLIC DISORDERS

      
Application Number 18454465
Status Pending
Filing Date 2023-08-23
First Publication Date 2024-03-14
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Khera, Amit
  • Agrawal, Saaket
  • Klarqvist, Marcus
  • Batra, Puneet

Abstract

The subject matter disclosed herein is generally directed to genetic variants associated with local adiposity traits and metabolic disease. Embodiments disclosed herein provide genetic variants associated with local adiposity traits obtained by adjusting adiposity traits for BMI and height. Embodiments disclosed herein also provide genes linked to variants and associated with the local adiposity traits. The local adiposity traits are associated with metabolic disorders. In example embodiments, variants indicate risk for a metabolic disorder and can be used to determine treatment. In example embodiments, genes associated with local adiposity traits and/or variants can be targeted therapeutically. In example embodiments, a risk for a metabolic disorder can be determined by detecting one or more risk variants associated with a local adiposity trait.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

90.

SYSTEM AND METHOD FOR HIGH-RESOLUTION, HIGH-SPEED CAPSULE ENDOMICROSCOPY

      
Application Number 18510253
Status Pending
Filing Date 2023-11-15
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo J.
  • Ryu, Jiheun

Abstract

A probe for performing endomicroscopy, including: a light source; a waveguide coupled to the light source; a diffraction grating, the waveguide directing light from the light source to the diffraction grating; and a lens having a first aspheric surface and a second biconic surface, diffracted light from the diffraction grating being directed into the aspheric surface of the lens and being emitted from the biconic surface of the lens towards a transparent cylindrical surface of the probe.

IPC Classes  ?

  • G02B 5/18 - Diffracting gratings
  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G02B 21/00 - Microscopes
  • G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes

91.

Extracellular mRNA Markers of Muscular Dystrophies in Human Urine

      
Application Number 18517748
Status Pending
Filing Date 2023-11-22
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Wheeler, Thurman
  • Breakefield, Xandra O.
  • Balaj, Leonora

Abstract

Described herein are methods for diagnosing and monitoring subjects with diseases associated with aberrant splicing, based upon detecting properly spliced isoforms and mis-spliced isoforms in a urine sample from the subject.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • C12Q 1/6865 - Promoter-based amplification, e.g. nucleic acid sequence-based amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

92.

MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES

      
Application Number 18210992
Status Pending
Filing Date 2023-06-16
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Elmaleh, David R.
  • Tanzi, Rudolph E.
  • Shoup, Timothy M.
  • Gircluc, Ana

Abstract

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

IPC Classes  ?

  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 311/22 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
  • C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

93.

METHODS AND COMPOSITIONS FOR INCREASING THE CONCENTRATION OF CELL FREE DNA

      
Application Number 18273922
Status Pending
Filing Date 2022-01-25
First Publication Date 2024-03-14
Owner
  • The Broad Institute, Inc. (USA)
  • Massachusetts Institute of Technology (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Adalsteinsson, Viktor A.
  • Tabrizi, Shervin
  • Bhatia, Sangeeta N.
  • Love, J. Christopher
  • Martin Alonso, Maria Carmen
  • Xiong, Kan

Abstract

This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA e analytical applications, such as sequencing applications.

IPC Classes  ?

  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • A61K 9/51 - Nanocapsules
  • A61K 38/00 - Medicinal preparations containing peptides

94.

CD64 CHIMERIC RECEPTOR AND USES THEREOF

      
Application Number 18272168
Status Pending
Filing Date 2022-01-18
First Publication Date 2024-03-14
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • CONSIGLIO NAZIONALE DELLE RICERCHE (Italy)
Inventor
  • Ferrone, Soldano
  • Sconocchia, Giuseppe
  • Caratelli, Sara

Abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes a chimeric receptor which comprises an CD64 binding domain, a transmembrane domain, and a CD3zeta signaling domain.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C07K 14/725 - T-cell receptors
  • C07K 14/735 - Fc receptors
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

95.

SYSTEMS AND METHODS FOR ATTENUATING ACOUSTIC WAVES

      
Application Number US2023073768
Publication Number 2024/054990
Status In Force
Filing Date 2023-09-08
Publication Date 2024-03-14
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Yun, Seok-Hyun
  • Shabahang, Soroush

Abstract

An acoustic filter can include a first substrate including a first plurality of holes directed, therethrough, a second substrate including a second plurality of holes directed therethrough, a chamber defined between the first substrate and the second substrate, and a membrane positioned within the chamber. The membrane can have a dimension other than the thickness of the membrane that can be less than a corresponding dimension of the chamber. The acoustic filter can be configured to attenuate a first acoustic wave that passes through the acoustic filter, the first acoustic wave can have a first amplitude above an amplitude threshold. The acoustic filter can be configured to passthrough a second acoustic wave without substantially attenuating the second acoustic wave, the second acoustic wave can have a second amplitude below' the amplitude threshold.

IPC Classes  ?

  • G10K 11/04 - Acoustic filters
  • A61F 11/08 - Protective devices for the ears internal, e.g. earplugs

96.

METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCE CONTIGUOUS TO A KNOWN TARGET NUCLEOTIDE SEQUENCE

      
Application Number 18459672
Status Pending
Filing Date 2023-09-01
First Publication Date 2024-03-07
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Iafrate, Anthony John
  • Le, Long Phi
  • Zheng, Zongli

Abstract

The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences.

IPC Classes  ?

  • C12Q 1/6855 - Ligating adaptors
  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

97.

AUTOMATED EVALUATION OF HUMAN EMBRYOS

      
Application Number 18507351
Status Pending
Filing Date 2023-11-13
First Publication Date 2024-03-07
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Shafiee, Hadi
  • Bormann, Charles
  • Kanakasabapathy, Manoj Kumar
  • Thirumalaraju, Prudhvi

Abstract

Systems and methods are provided for provided for automatic evaluation of a human embryo. An image of the embryo is obtained and provided to a neural network to generate a plurality of values representing the morphology of the embryo. The plurality of values representing the morphology of the embryo are evaluated at an expert system to provide an output class representing one of a current quality of the embryo, a future quality of the embryo, a likelihood that implantation of the embryo will be successful, and a likelihood that implantation of the embryo will result in a live birth.

IPC Classes  ?

98.

Methods for Detecting Site-Specific and Spurious Genomic Deamination Induced by Base Editing Technologies

      
Application Number 18339788
Status Pending
Filing Date 2023-06-22
First Publication Date 2024-03-07
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Angstman, James
  • Gehrke, Jason Michael

Abstract

Methodologies to detect off-target mutations induced by the deaminase activity of Base Editing technology.

IPC Classes  ?

  • C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
  • C12Q 1/6855 - Ligating adaptors
  • C12Q 1/6869 - Methods for sequencing

99.

PERFUSABLE 3D TUBULE-ON-CHIP MODEL DERIVED FROM KIDNEY ORGANOIDS WITH IMPROVED DRUG UPTAKE

      
Application Number US2023073271
Publication Number 2024/050497
Status In Force
Filing Date 2023-09-01
Publication Date 2024-03-07
Owner
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Aceves, Jeffrey, O.
  • Wolf, Kayla
  • Robinson, Sanlin, S.
  • Morizane, Ryuji
  • Lewis, Jennifer
  • Van Gaal, Ronald

Abstract

Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.

IPC Classes  ?

  • A61K 35/545 - Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
  • A61K 35/22 - Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland

100.

Polypeptide Integrin Antagonists

      
Application Number 18317017
Status Pending
Filing Date 2023-05-12
First Publication Date 2024-03-07
Owner The General Hospital Corporation (USA)
Inventor Arnaout, M. Amin

Abstract

The present application relates to polypeptides which are integrin antagonists. Methods of preparing the integrin antagonists and methods of treating diseases and disorders associated with abnormal levels and/or expression of one or more integrins are also provided.

IPC Classes  ?

  • C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 7/04 - Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  1     2     3     ...     46        Next Page